The New York Times’ John Schwartz asks Eric Dezenhall about why Martin Shkreli the Turing Pharmaceutical executive who raised its drug Daraprim price to $750 a pill from $13.50 was vilified so quickly. Read the article for Eric’s simple answer.
Sign up for the Glass Jaw Substack Newsletter
A newsletter about defending fragile reputations in an era of instant scandal.
Subscribe
Your submission has been sent. A staff member will reach out to you shortly. In the meantime, please view our recent case studies.
